TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Greek NIS Spiolto ELLACTO

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Therapeutic indication before entering the enrollment face is patients diagnosed with COPD requiring a combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and guidelines, COPD GOLD 2017 groups B to D~* Female and male patients ≥40 years of age~* Treatment with Spiolto ® Respimat® acc. to SmPC and at the discretion of the physician~* Written informed consent prior to participation~Exclusion Criteria:~* Patients with contraindications according to Spiolto® Respimat® SmPC~* Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 weeks or patients already on a combination of LAMA and LABA therapy; either as a fixed combination product or as separate components Note: Patients previously treated with LABA or LAMA (with or without ICS) are eligible to be included in the study~* Patients continuing LABA-ICS treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~* Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks~* Pregnancy and lactation~* Patients currently listed for lung transplantation~* Current participation in any clinical trial or any other non-interventional study of a drug or device

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COPD patients (Type: None): Chronic obstructive pulmonary disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be Chinese~* Must have a diagnosis of bilateral nasal polyps~* Clinically significant nasal congestion/obstruction must be present~* Must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures, or compromise the participant's safety~* Must have negative urine pregnancy test~* Must be using or agree to use a medically accepted method of contraception prior to Screening and during the study~Exclusion Criteria:~* Have a history of seasonal allergic rhinitis within the last two years~* Have had sinus or nasal surgery within the past six months~* Have presumed fibrotic nasal polyps~* Have had three or more nasal surgeries~* Have had any surgical procedure that prevents an accurate grading of the polyps~* Complete (or near complete) nasal obstruction~* Have acute sinusitis, concurrent nasal infection or have had a nasal infection within two weeks~* Have ongoing rhinitis medicamentosa~* Have Churg Strauss syndrome (vasculitis, asthma, fever, and eosinophilia)~* Have dyskinetic ciliary syndromes, eg, Young's syndrome (sinopulmonary infections and obstructive azoospermia) or Kartagener's syndrome (immobile cilia)~* Have been treated within the last 4 weeks with intranasal steroids~* Have used any investigational drug in the last 30 days~* Have a hypersensitivity to corticosteroids or are allergic to aspirin~* Have an ongoing upper respiratory tract infection or had an upper respiratory tract infection within two weeks~* Have a nasal septal deviation needing corrective surgery~* Have a nasal septal perforation~* Have asthma that required in-patient hospitalization for asthma control within six months, required ventilator support for respiratory failure secondary to their asthma within the last five years, required admission to the hospital for management of airway obstruction on two or more occasions within the past year, or required use of more than 14 days of systemic steroid use in previous six months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate Nasal Spray (MFNS) (Type: EXPERIMENTAL): Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive matching placebo nasal spray BID for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 1~* Has a FEV1 measured at least 6 hours after the last dose of inhaled, short-acting β2-agonist (SABA) and at least 48 hours after the last dose of inhaled long-acting β2-agonist of =60% and =85% of predicted normal.~* Demonstrated reversibility of FEV1 of =15% from pre short acting beta agonist level within 15 to 30 minutes after administration of a standard dose of short acting beta agonist~Exclusion Criteria:~* Has been hospitalized for \>24 hours at least once or required emergency treatment or urgent care visit more than once for an asthma-related condition during the 6 months prior to Visit 1~* Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 1.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- BUD 160/FM 2.25 (Type: EXPERIMENTAL): 2.25 μg formoterol (as 80/2.25 μg Symbicort pMDI × 1 inhalation) + 40 μg budesonide HFA pMDI × 2 inhalations
- BUD 160/FM 4.5 (Type: EXPERIMENTAL): placebo HFA pMDI × 1 inhalation + 4.5 μg formoterol (as 80/2.25 μg Symbicort pMDI × 2 inhalations)
- BUD 160/FM 9.0 (Type: EXPERIMENTAL): placebo HFA pMDI × 1 inhalation + 9 μg formoterol (as 80/4.5 μg Symbicort pMDI × 2 inhalations)
- BUD 160 (Type: PLACEBO_COMPARATOR): placebo HFA pMDI × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
- BUD 160/Foradil 12.0 (Type: ACTIVE_COMPARATOR): Foradil Aerolizer 12 μg × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetes mellitus~* Established diabetic therapy for at least 3 months~* Lab-supported diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy~* Pain the previous three months~* Not pregnant~Exclusion Criteria:~* Patient failed adequate trial of 3 or more medications or has required narcotics for pain~* History of torsades de pointes~* Sensitivity to quinidine or opiate drugs (codeine, etc)~* Severe pain that could confound the assessment~* Patient has had any amputations~* Patient has participated in the past 30 days or is currently participating in another trial~* Patient has previously received treatment with dextromethorphan and quinidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Scalp psoriasis amenable to topical treatment with a maximum of 100 g of medication per week~* Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs~* Extent of scalp psoriasis involving more than 10% of the total scalp area~* Investigator's assessment of clinical signs of the scalp of at least 2 in one of the clinical signs, erythema, thickness and scaliness, and at least 1 in each of the other two clinical signs~* Disease severity on the scalp graded as Mild, Moderate, Severe or Very severe according to the investigator's global assessment of disease severity~Exclusion Criteria:~* PUVA or Grenz ray therapy within 4 weeks prior to randomisation~* UVB therapy within 2 weeks prior to randomisation~* Systemic treatment with biological therapies, with a possible effect on scalp psoriasis within 6 months prior to randomisation~* Systemic treatment with all other therapies than biologicals, with a possible effect on scalp psoriasis (e.g., corticosteroids, vitamin D analogues, retinoids, immunosuppressants) within 4 weeks prior to randomisation~* Any topical treatment of the scalp (except for medicated shampoos and emollients) within 2 weeks prior to randomisation~* Topical treatment of the face, trunk and/or limbs with very potent WHO group IV corticosteroids within 2 weeks prior to randomisation~* Current diagnosis of erythrodermic, exfoliative or pustular psoriasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab in Metastatic Renal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced and/or metastatic renal cell cancer~* No contraindications for Avastin according to summary of product characteristics (SmPC)~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced and/or Metastatic RCC participants (Type: None): Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a postmenopausal female 40 to 75 years of age~* Patient has a Body Mass Index (BMI) less than or equal to 35 kg/m2~* Patient has a documented history of overactive bladder for at least 6 months prior to screening~Exclusion Criteria:~* Patient has stress or mixed incontinence~* Patient has a history of interstitial cystitis, painful bladder syndrome, or chronic pelvic pain~* Patient has a history of stroke, seizures, or major neurological disorders~* Patient has a history of fecal incontinence~* Patient has a history of continual urine leakage~* Patient has had surgery to correct stress urinary incontinence or pelvic organ prolapse within 6 months of study start~* Patient received bladder training of electrostimulation within 2 weeks of study start~* Patient requires a catheter~* Patient is taking medications that cannot be stopped for the duration of the trial including certain anticholinergics or smooth muscle relaxants~* Patient began taking tricyclic antidepressants, serotonin/norepinephrine reuptake inhibitors, calcium channel blockers, ephedrine/pseudoephedrine, or diuretic therapy less than 8 weeks before study start~* Patient has been on hormone replacement therapy for less than 12 weeks at study start~* Patient must take medication for arrhythmia~* Patient consumes more than 2 alcoholic beverages per day~* Patient consumes more than 3 servings of caffeinated beverages per day (1 serving = 120 mg caffeine)~* Patient has multiple and/or severe allergies to foods and drugs~* Patient regularly uses any illegal drugs

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
- 2 (Type: EXPERIMENTAL): Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
- 3 (Type: EXPERIMENTAL): Part II, Sequence 1: study drug crossing over to placebo
- 4 (Type: EXPERIMENTAL): Part II, Sequence 2: placebo crossing over to study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Staccato Loxapine in Agitated Patients With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adult patients with bipolar 1 disorder and acute agitation~Exclusion Criteria:~* Agitation caused primarily by acute intoxication~* History of drug or alcohol dependence~* Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled Placebo (Type: PLACEBO_COMPARATOR): Inhaled Staccato Placebo, may repeat after 2 hours x 2
- Inhaled Loxapine 5 mg (Type: EXPERIMENTAL): Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
- Inhaled Loxapine 10 mg (Type: EXPERIMENTAL): Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and Female, from 18 to 75 years old;~* Established diagnosis of CHD;~* Previous (at least, within 1 month before inclusion in the present study) treatment with statin;~* Levels of plasma TC and LDL-C above the recommended target values~(TC\> 4.5 mmol\\L; LDL-C\> 2.5 mmol/L);~* The written informed consent signed prior to the start of participation in the study.~Exclusion Criteria:~* Contraindications for statin and ezetimibe (Ezetrol) administration in accordance with local Russian Federation medical instructions.~* Patients refused to participate in the study and/or did not sign informed consent form.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- New Statin (Type: None): Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
- Statin Dose Titration (Type: None): Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
- Ezetimibe added to existing statin (Type: None): Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women who are 20 - 75 years old~* HbA1c of ≥7.0% and \<10.5%~* FPG of ≤ 270 mg/dL~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before run-in period~Exclusion Criteria:~* Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes~* Patients with serious diabetic complications~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification~* Patients with severe hepatic disorder or severe renal disorder.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Teneligliptin + Canagliflozin (Type: EXPERIMENTAL): Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
- Placebo + Canagliflozin (Type: PLACEBO_COMPARATOR): Patients receive placebo for 24 weeks in combination with Canagliflozin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 20 years old~* 7g/dl ≤ Hb \< 10g/dl at 5 - 7 days after gastrectomy for gastric cancer~* signed written informed consent~Exclusion Criteria:~* a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient~* hypersensitivity to any component of the formulation~* active severe infection/inflammation~* History of transfusion, erythropoietin, \> 500 mg intravenous iron administration within 4 weeks prior to screening.~* History of acquired iron overload.~* Pregnancy or lactation.~* Decreased renal function (defined as creatinine clearance \< 50 mL/min calculated by Cockcroft-Gault)~* Chronic liver disease or increase of liver enzymes (ALT, AST) \> 3 times the upper limit of normal range.~* Participation in any other interventional study within 1 month prior to screening.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject® Group (Type: EXPERIMENTAL): Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb\<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb\<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3-18~* Speech disorders verified by speech therapist and neurologist~* Adequate hearing/vision to follow conversation~* Russian speaker~* A written informed consent of the parents/close relatives~Exclusion Criteria:~* Acute infectious disease (bacterial, fungal, or viral)~* Seizures~* Intolerance to gentamicin and/or multiple drug allergies~* Participation in other clinical trials

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal M2-BFs (Type: EXPERIMENTAL): Intranasally-Administered Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). M2 were generated in vitro from peripheral blood of a parent during 7 days. Cell-free culture medium, containing M2-BFs, was collected, and aliquots of 2 mL/vial were cryopreserved.~30 children with speech disorders will receive their first doses (n=2-3) of M2-BFs in Clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose. The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete